Fosun Pharma (600196.SH) released its semi-annual performance, with a net profit attributable to the parent of 1.702 billion yuan, an increase of 38.96% year-on-year.

News from Sina Finance APP, Fosun Pharma (600196.SH) released its 2025 interim report. During the reporting period, the company achieved operating income of 19.514 billion yuan, a year-on-year decrease of 4.63%. Net profit attributable to shareholders of the listed company was 1.702 billion yuan, a year-on-year increase of 38.96%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.961 billion yuan, a year-on-year decrease of 23.39%. Basic earnings per share were 0.64 yuan.